How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,855 results for

Imiquimod

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1681. Topical imiquimod treatment prevents UV-light induced loss of contact hypersensitivity and immune tolerance. Full Text available with Trip Pro

Topical imiquimod treatment prevents UV-light induced loss of contact hypersensitivity and immune tolerance. Imiquimod (1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine) is a TLR7 agonist that induces cytokine production in TLR7 bearing antigen-presenting cells (APCs), including IL-12, a cytokine that has been demonstrated to be a critical effector molecule for contact hypersensitivity (CHS). To test our hypothesis that topical applications of imiquimod may protect the skin immune system (...) against the deleterious effects of UV light exposures, we treated animals with this agent, or its vehicle or nothing before UV exposures. Although topical imiquimod exposures before UV light did not prevent the depletion of epidermal Langerhans cells, it did prevent the loss of CHS. IL-12 was important in the protective role of imiquimod in preventing UV-induced loss of CHS, as systemic treatment of mice with an anti-IL-12 p70 monoclonal antibody blocked the protective effects of imiquimod

2006 Journal of Investigative Dermatology

1682. The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7- and TLR8-independent fashion. Full Text available with Trip Pro

The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7- and TLR8-independent fashion. Imiquimod, a small-molecule immune response modifier of the imidazoquinoline family, has shown profound antitumoral and antiviral efficacy both in vitro and in clinical applications in vivo. It has been demonstrated that this activity is mediated through the Toll-like receptor (TLR)7- and TLR8-signaling cascade resulting in the secretion (...) of proinflammatory cytokines and, consecutively, induction of a tumor-directed cellular immune response. In addition, imiquimod exerts a direct proapoptotic activity in tumor cells. We demonstrate here that imiquimod induces activation of the transcription factor NF-kappaB and the downstream production of proinflammatory cytokines in the absence of TLR7 and TLR8. In Chinese hamster ovary cells stably transfected with the human adenosine receptor subtypes, we then show in radioligand-binding competition

2006 Journal of Investigative Dermatology

1683. Does imiquimod histologically rejuvenate ultraviolet radiation-damaged skin? (Abstract)

Does imiquimod histologically rejuvenate ultraviolet radiation-damaged skin? Imiquimod (IMI) 5% is believed by some to result in an improved cosmetic appearance of chronically ultraviolet radiation (UV)-damaged skin.The objective was to determine what histologic and immunohistologic changes were present in actinically damaged skin after treatment with IMI.Pre- and posttherapy biopsies of 12 patients with histories of actinic keratoses were evaluated with routine histology

2007 Dermatologic Surgery

1684. Imiquimod treatment induces expression of opioid growth factor receptor: a novel tumor antigen induced by interferon-alpha? Full Text available with Trip Pro

Imiquimod treatment induces expression of opioid growth factor receptor: a novel tumor antigen induced by interferon-alpha? Imiquimod represents a synthetic local immune response modifier that has demonstrated efficacy in clearing basal cell carcinoma. Via interaction with Toll-like receptor 7 on immune cells, imiquimod induces local production of cytokines, such as interferon (IFN)-alpha.To more closely define and elucidate mechanisms leading to basal cell carcinoma clearance in vivo, we (...) examined gene expression profiles of skin basal cell carcinoma before and after treatment with 5% imiquimod cream (Aldara) by using high-density oligonucleotide arrays.We show that imiquimod predominantly induces genes involved in different aspects of immune response. In addition to effects on immunity, imiquimod treatment modulates the expression of genes involved in the control of apoptosis and oncogenesis. Array data indicated that imiquimod treatment induces expression of opioid growth factor

2004 Clinical Cancer Research

1685. Detection of human papillomavirus (HPV) 16-specific CD4+ T-cell immunity in patients with persistent HPV16-induced vulvar intraepithelial neoplasia in relation to clinical impact of imiquimod treatment. Full Text available with Trip Pro

Detection of human papillomavirus (HPV) 16-specific CD4+ T-cell immunity in patients with persistent HPV16-induced vulvar intraepithelial neoplasia in relation to clinical impact of imiquimod treatment. Topical application of the immune response modifier imiquimod is an alternative approach for the treatment of human papillomavirus (HPV)-positive vulvar intraepithelial neoplasia (VIN) and aims at the immunologic eradication of HPV-infected cells. We have charted HPV16-specific immunity in 29 (...) patients with high-grade VIN and examined its role in the clinical effect of imiquimod treatment.The magnitude and cytokine polarization of the HPV16 E2-, E6-, and E7-specific CD4+ T-cell response was charted in 20 of 29 patients by proliferation and cytokine bead array. The relation between HPV16-specific type 1 T-cell immunity and imiquimod treatment was examined in a group of 17 of 29 patients.HPV16-specific proliferative responses were found in 11 of the 20 patients. In eight of these patients, T

2005 Clinical Cancer Research

1686. Treatment of bowenoid and basaloid vulvar intraepithelial neoplasia 2/3 with imiquimod 5% cream. (Abstract)

Treatment of bowenoid and basaloid vulvar intraepithelial neoplasia 2/3 with imiquimod 5% cream. To evaluate the effectiveness and safety of imiquimod 5% for the treatment of bowenoid and basaloid vulvar intraepithelial neoplasia (VIN) and to evaluate recurrences following treatment.Eight patients <55 years old (range, 32-51; mean, 39.7), with bowenoid or basaloid VIN 2/3 diagnosed by biopsy were treated with imiquimod 5%. Women with other types of intraepithelial neoplasia of the lower genital (...) tract, immunosuppressed women, pregnant women and women with other types of vulvar pathology were excluded. Two patients previously treated for VIN 3 (surgical resection, resection by loop electrosurgical excision procedure) had recurrences. Patients applied imiquimod cream 3 times a week until total clearance of the lesions or up to a maximum of 16 weeks. Responses were categorized as total when there was no colposcopic evidence of a lesion, partial when the lesion area diminished >50

2004 Journal of Reproductive Medicine

1687. Pyogenic granuloma in children: Treatment with topical imiquimod. (Abstract)

Pyogenic granuloma in children: Treatment with topical imiquimod. We report the successful treatment of five children with facial pyogenic granuloma using topical imiquimod 5% cream. In all cases, resolution of the lesions was achieved within 2-4 weeks. Local erythema and scaling, consistent with a typical imiquimod response, was the most commonly observed side effect. No systemic complications were observed in any of the patients. There has been no recurrence of any of the lesions to date

2007 Australasian Journal of Dermatology

1688. Human papillomavirus-type predict the clinical outcome of imiquimod therapy for women with vulvar condylomata acuminata. (Abstract)

Human papillomavirus-type predict the clinical outcome of imiquimod therapy for women with vulvar condylomata acuminata. To investigate the effect of determination of human papillomavirus (HPV) subtype on the success of imiquimod therapy in women with vulvar condylomata acuminata.A total of 132 women with biopsy-proven vulvar condylomata acuminata were enrolled in this prospective study. HPV DNA detection and determination of genotype were made through polymerase chain reaction (PCR) technique (...) . The women were treated with imiquimod cream 5% in the area of the visible lesions, three times a week at night for 16 weeks.Twelve of the 132 women (9.1%) failed to detect any improvement with this therapy during the 16-week period. However, 80 women (60.6%) experienced total clearance of the lesions, and 20 women (15.2%) observed a partial response. The complete response rates were 76.2% for HPV-6, 66.7% for HPV-11, 35% for HPV-6 plus 11, and 6.3% for unclassified HPV subtypes (other HPV subtypes than

2007 Acta Obstetricia et Gynecologica Scandinavica

1689. Multiple and clustered eruptive epidermoid cysts following treatment with topical imiquimod. (Abstract)

Multiple and clustered eruptive epidermoid cysts following treatment with topical imiquimod. A 61-year-old woman developed multiple and clustered eruptive epidermoid cysts at the site of treatment of a basal cell carcinoma located on her nose with imiquimod 5% cream (5 times/week for 6 weeks). Clearing was achieved after topical treatment with tretinoin 0.025% cream (1 application/day for 1 month).2007 S. Karger AG, Basel

2007 Dermatology

1690. Angiolymphoid hyperplasia with eosinophilia successfully treated with imiquimod. A case report. (Abstract)

Angiolymphoid hyperplasia with eosinophilia successfully treated with imiquimod. A case report. Angiolymphoid hyperplasia with eosinophilia (ALHE) is a rare disorder characterized by vascular proliferation, eosinophilia in peripheral blood samples and lymphocytosis. The etiology is unknown; this rare condition is generally seen in women. It often presents as multiple, grouped red nodules in the periauricular region, scalp line and neck. Numerous therapeutic approaches have been tried for ALHE (...) including destructive techniques such as electrodesiccation, cryotherapy, surgical excision, radiotherapy or laser (argon, CO(2), pulse dye). We present an ALHE case that was treated successfully by using topical imiquimod cream.Copyright 2007 S. Karger AG, Basel.

2007 Dermatology

1691. Progressive ORF virus infection in a patient with lymphoma: successful treatment using imiquimod. Full Text available with Trip Pro

Progressive ORF virus infection in a patient with lymphoma: successful treatment using imiquimod. Orf virus is a parapoxvirus that infects small ruminants worldwide. We present the case report of a 73-year-old woman with non-Hodgkins lymphoma who developed progressive orf virus lesions that were unresponsive to surgical debridement and to cidofovir therapy. The patient's orf virus infection was successfully treated with topical imiquimod despite progression of her malignancy.

2007 Clinical Infectious Diseases

1692. Selective defect in plasmacyoid dendritic cell function in a patient with AIDS-associated atypical genital herpes simplex vegetans treated with imiquimod. Full Text available with Trip Pro

Selective defect in plasmacyoid dendritic cell function in a patient with AIDS-associated atypical genital herpes simplex vegetans treated with imiquimod. We report a case of acquired immunodeficiency syndrome (AIDS)-associated, acyclovir-refractory genital herpes infection treated with topical imidazoquinoline therapy. The patient's plasmacytoid dendritic cells made a robust interferon- alpha response following in vitro stimulation with imidazoquinoline but not with herpes simplex virus. We

2007 Clinical Infectious Diseases

1693. Preliminary results of 5% imiquimod cream in the primary treatment of vulva intraepithelial neoplasia grade 2/3. (Abstract)

Preliminary results of 5% imiquimod cream in the primary treatment of vulva intraepithelial neoplasia grade 2/3. This study was undertaken to study the tolerability and efficacy of 5% imiquimod cream in the primary treatment of vulva intraepithelial neoplasia (VIN) grade 2/3.VIN grade 2/3 patients were recruited from regional colposcopy units. Imiquimod cream was applied over the abnormal area by the patient using an escalating dose regime for total treatment duration of 16 weeks. At the end

2006 American Journal of Obstetrics and Gynecology

1694. Immunotherapy with imiquimod 5% cream for eyelid nodular basal cell carcinoma. (Abstract)

Immunotherapy with imiquimod 5% cream for eyelid nodular basal cell carcinoma. To evaluate the efficacy and safety of topical imiquimod 5% cream for the treatment of eyelid basal cell carcinoma.Two interventional case reports.Imiquimod 5% cream was applied topically once daily, 3 days a week for 8 to 12 weeks, in two patients affected by eyelid nodular basal cell carcinoma. Patients were followed up clinically with slit-lamp examination for evidence of tumor disappearance or recurrence (...) , and local and systemic side effects.Complete clinical response was obtained in both patients. No severe local side effects were observed. Patients did not show any local recurrence after 1 year.Topical imiquimod 5% cream seems to be a useful treatment for eyelid nodular basal cell carcinoma in selected cases, but further long-term studies are needed to assess the efficacy and safety of this approach.

2005 American Journal of Ophthalmology

1695. Imiquimod in vulvar Paget's disease: a case report. (Abstract)

Imiquimod in vulvar Paget's disease: a case report. Vulvar Paget's disease is a relatively rare gynecologic neoplasm that is problematic because of its propensity to recur.An 80-year-old woman was found to have recurrent Paget's disease of the vulva. She was initially diagnosed 12 years previously and had had multiple resections for the disease. She was found to have histologically proven Paget's disease and underwent a course of topical immune modulator therapy with imiquimod. Biopsy proved (...) histologic regression of the disease progress. The patient remained without recurrence 12 months after therapy.In select patients imiquimod may be used to treat or facilitate treatment of vulvar Paget's disease.

2008 Journal of Reproductive Medicine

1696. Peculiar clinical and dermoscopic remission pattern following imiquimod therapy of basal cell carcinoma in seborrhoeic areas of the face. (Abstract)

Peculiar clinical and dermoscopic remission pattern following imiquimod therapy of basal cell carcinoma in seborrhoeic areas of the face. Imiquimod is a 240.3-Da synthetic imidazoquinolinamine (C14H16N4), developed in 1983 and approved in 1997 by the US Food and Drug Administration for the topical treatment of external genital and perianal warts and, more recently, also for actinic keratosis and superficial basal cell carcinomas. We report five cases of patients affected by basal cell (...) carcinomas localized in seborrhoeic areas of the face, successfully treated with topical imiquimod and characterized by the occurrence of eruptive epidermoid cysts at the end-point of therapy. The dermatoscopic evaluation disclosed the presence in all lesions of a common feature characterized by a hyperkeratotic yellow-withish area, resembling 'popcorn', excluding dermoscopic basal cell carcinoma features. Furthermore, histological proof confirmed the diagnosis of epidermoid cysts. As reported

2008 Journal of Dermatological Treatment

1697. Pityriasis rubra pilaris exacerbation with topical use of imiquimod. (Abstract)

Pityriasis rubra pilaris exacerbation with topical use of imiquimod. The role of immune response modifiers is increasing in the treatment of dermatologic diseases. Imiquimod, a toll-like receptor agonist, results in up-regulation of proinflammatory cytokines for improved immune surveillance. Although topical use is generally well-tolerated, imiquimod can potentially result in systemic effects and exacerbate generalized inflammatory papulosquamous diseases of the skin. We report the case of a 67 (...) -year-old man who was treated with imiquimod for actinic keratosis and developed fever and a progressive erythematous papulosquamous eruption that was histologically consistent with pityriasis rubra pilaris.

2008 International Journal of Dermatology

1698. Lentigo Maligna Managed with Topical Imiquimod and Dermoscopy: Report of Two Cases. (Abstract)

Lentigo Maligna Managed with Topical Imiquimod and Dermoscopy: Report of Two Cases. 18798748 2008 12 18 2018 12 01 1524-4725 34 11 2008 Nov Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] Dermatol Surg Lentigo maligna managed with topical imiquimod and dermoscopy: report of two cases. 1561-6 10.1111/j.1524-4725.2008.34322.x de Troya-Martín Magdalena M Department of Dermatology, Hospital Costa del Sol, Marbella, Spain. magdatm@hcs.es Frieyro (...) -Elicegui Marta M Fúnez Liébana Rafael R Aguilar Bernier Miguel M Fernández-Canedo N Ines NI Blázquez Sánchez Nuria N eng Case Reports Journal Article 2008 09 15 United States Dermatol Surg 9504371 1076-0512 0 Aminoquinolines 0 Antineoplastic Agents P1QW714R7M Imiquimod IM Administration, Topical Aged, 80 and over Aminoquinolines administration & dosage Antineoplastic Agents administration & dosage Dermoscopy Female Humans Hutchinson's Melanotic Freckle drug therapy pathology Imiquimod Male Skin

2008 Dermatologic Surgery

1699. Localized morphea treated with imiquimod 5% and dermoscopic assessment of effectiveness. (Abstract)

Localized morphea treated with imiquimod 5% and dermoscopic assessment of effectiveness. The cases are reported of two women patients presenting asymptomatic solitary lesions: one in the anterior tibial region of the right leg, the other on the right arm. The first patient's lesion was 3 cm in diameter and had appeared 2 years earlier as a translucent oval atrophic patch with a definite border. The second patient presented a whitish area with a lilac ring, 2.5 cm in diameter, which had appeared (...) nearly a year earlier. Both patients had no other similar cutaneous lesions, and their family histories for cutaneous disease were negative. The lesions underwent punch biopsy, and the histopathological findings confirmed the diagnosis of morphea. Laboratory investigations showed no abnormalities. Imiquimod 5% cream was prescribed for 5 consecutive days a week for 16 weeks. Clinical and dermoscopic assessment of the lesions was performed before treatment, during follow-up and at treatment end point

2008 Journal of Dermatological Treatment

1700. Confirmation of histological clearance of superficial basal cell carcinoma with multiple serial sectioning and Mohs' micrographic surgery following treatment with imiquimod 5% cream. (Abstract)

Confirmation of histological clearance of superficial basal cell carcinoma with multiple serial sectioning and Mohs' micrographic surgery following treatment with imiquimod 5% cream. Although the effectiveness of daily dosing regimens of 5% imiquimod cream for the treatment of superficial basal cell carcinomas (sBCC) has been documented by recent studies, concerns about long-term outcome remain. The majority of efficacy data is based on clinical clearance and limited histological examination (...) which may not identify tumour presence at the periphery.To assess the efficacy of 5% imiquimod cream for sBCC using detailed histological assessment 1 year after completion of treatment.Nine individuals with biopsy-proven sBCC treated with 5% imiquimod cream 1 year previously and who remained clinically clear were recruited. Paraffin-embedded excision specimens from the original tumour site were extensively examined by a dermatopathologist. Examination and analysis of frozen sections of the original

2008 Journal of Dermatological Treatment

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>